Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer announced on Sept. 30 it will participate in a new government direct-to-consumer drug sale website. TrumpRx, which is expected to launch at the beginning of next year, will allow patients to ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...